Accession Number:

ADA586996

Title:

North American Clinical Trials Network (NACTN) for Treatment of Spinal Cord Injury: A Consortium of Military, Veterans Administration and Civilian Hospitals

Descriptive Note:

Final rept. 14 may 2007-13 Apr 2009

Corporate Author:

CHRISTOPHER REEVE FOUNDATION SHORT HILLS NJ

Report Date:

2009-05-01

Pagination or Media Count:

14.0

Abstract:

Amnion Derived Multipotent Progenitor Cells AMPCs and their secreted amnion-derived cellular cytokine suspension ACCS may have the potential to enhance wound healing and tissue repair. The objective of this proposal is to test the ability of AMPCs and ACCS to effect recovery after spinal cord injury SCI, according to two hypothesis-driven goals A Does acute 2 day delay AMP cell transplantation after SCI improve functional locomotor recovery and histological injury measures and B Is ACCS sufficient to promote recovery of function after SCI, or synergistic when administered in combination with AMP cells AMPCs and ACCS will be transplanted into a well-established model of contusion induced SCI, contusion injury being the most common and clinically relevant form of damage in the human clinical population, according to the experimental parameters of the hypotheses outlined under the objectives and in the detailed experimental design. Regaining partial function can lead to improved functional mobility and sensation, improving quality of life and reducing lifetime costs associated with SCI.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE